Revenue fell 11.63% and net profit dropped 48.50% year-over-year, mainly due to lower international sales and margin pressure on instruments. Operating cash flow turned negative, while R&D investment remained high. The company will focus on reagent sales growth, cash flow, and international expansion in 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.